Ischemic Heart Disease (IHD) Drugs Market Forecast Through 2030 With Insights On Market Patterns And Developments
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Ischemic Heart Disease (IHD) Drugs Market Projected To Reach By 2030?
The ischemic heart disease (ihd) drugs market has experienced consistent expansion in recent years. It is anticipated to increase from $6.65 billion in 2025 to $6.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.7%. This historical growth can be attributed to several factors, including the rising incidence of coronary artery disease, an expanding elderly population, increased public awareness regarding cardiovascular health, a high prevalence of lifestyle-related risk factors, and the availability of generic drugs.
The ischemic heart disease (ihd) drugs market size is anticipated to experience consistent expansion over the next few years. It is projected to increase to $7.99 billion by 2030, with a compound annual growth rate (CAGR) of 3.7%. This growth during the forecast period is attributable to advancements in precision medicine, the integration of digital health solutions, the rising adoption of combination therapy, the development of innovative drug delivery systems, and the broadening reach of telehealth and remote monitoring. Significant trends for the forecast period include personalized cardiac therapy, multi-drug formulations, telemedicine-supported cardiac care, cardiovascular risk prediction and monitoring, and minimally invasive drug delivery methods.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Which Strong Drivers Are Impacting The Ischemic Heart Disease (IHD) Drugs Market Growth?
The escalating occurrence of heart failure is anticipated to drive the expansion of the ischemic heart disease (IHD) drug market in the foreseeable future. Heart failure is defined as a chronic condition where the heart muscle is unable to pump sufficient blood to meet the body’s requirements for blood and oxygen, often leading to fatigue, shortness of breath, and difficulties with everyday activities. Ischemic heart disease (IHD) drugs play a vital role in treating heart failure. These medications can help avert heart failure by reducing the risk factors and symptoms associated with ischemic heart disease. Ischemic heart disease (IHD) drugs function by inhibiting the heart’s pacemaker activity, which proves beneficial for heart failure patients with reduced ejection fractions and high resting heart rates, especially after a tolerated beta-blocker. For instance, according to the Heart Failure Society of America, a US-based organization, in September 2023, 6.7 million Americans over 20 years of age were affected by heart failure (HF), with projections indicating a rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is a key factor boosting the growth of the ischemic heart disease (IHD) drug market.
How Is The Ischemic Heart Disease (IHD) Drugs Market Segmented Across Different Segment Categories?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Which Trends Are Shaping The Ischemic Heart Disease (IHD) Drugs Market?
Leading companies within the ischemic heart disease (IHD) drugs sector are prioritizing expedited regulatory clearances and the broadening of drug indications to enhance therapeutic alternatives and secure a larger market share. For instance, in June 2023, the US-based biopharmaceutical company Bristol Myers Squibb announced that the European Commission granted approval for Camzyos (mavacamten), which stands as the first allosteric, selective cardiac myosin inhibitor for the treatment of symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). In the same year, in the U.S., the FDA approved a supplemental new drug application, supported by Phase 3 VALOR HCM data, demonstrating a notable decrease in eligibility for septal reduction therapy among patients who received the treatment. Consequently, the growing regulatory momentum and expanded approved uses for myosin inhibitors are propelling the growth within the IHD drug market.
Which Organizations Play A Role In The Ischemic Heart Disease (IHD) Drugs Market Landscape?
Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC
Get The Full Ischemic Heart Disease (IHD) Drugs Market Report:
Where Is The Ischemic Heart Disease (IHD) Drugs Market Primarily Concentrated By Region?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Ischemic Heart Disease (IHD) Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2026, By The Business Research Company
Ischemic Heart Disease Ihd Drugs Market Report 2026
Acute Ischemic Stroke Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
